Domino Ring-Closing Enyne-Metathesis-Cross-Metathesis Approach to 1-Phosphonylated Benzazepines

Nicolai Dieltiens; Christian V. Stevens

doi:10.1055/s-2006-950262

Subscribe to RSS

Please copy the URL and add it into your RSS Feed Reader.

https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000083.xml

Share / Bookmark

Facebook X Linkedin Weibo

Download PDF

Synlett 2006(17): 2771-2776
DOI: 10.1055/s-2006-950262

LETTER

Domino Ring-Closing Enyne-Metathesis-Cross-Metathesis Approach to 1-Phosphonylated Benzazepines

Nicolai Dieltiens, Christian V. Stevens*
Research Group SynBioc, Department of Organic Chemistry, Faculty of Bioscience Engineering, Ghent University, Coupure Links 653, 9000 Ghent, Belgium
Fax: +32(9)2646243; e-Mail: chris.stevens@UGent.be;

Further Information

Publication History

Received 8 August 2006
Publication Date:
09 October 2006 (online)

Abstract
Full Text
References

Permissions and Reprints All articles of this category

Abstract

A short approach was developed towards phosphonylated benzazepines. Aminophosphonates containing an ‘yne’ and an ‘ene’ moiety were synthesised via phosphonylation of the corresponding imines. The key step in the reaction sequence is a domino enyne-metathesis-cross-metathesis.

Key words

domino reactions - enynes - fused-ring systems - metathesis - phosphorus

References and Notes

1 Horton DA. Bourne GT. Smythe ML. Chem. Rev. 2003, 103: 893

Crossref PubMed Google Scholar
2a Arany A. Groundwater PW. Nyerges M. Tetrahedron Lett. 1998, 39: 3267

Article in Thieme Connect Google Scholar
2b Arany A. Bendell D. Groundwater PW. Garnett I. Nyerges M. J. Chem. Soc., Perkin Trans. 1 1999, 2605

Article in Thieme Connect Google Scholar
2c Gerdes K. Sagar P. Fröhlich R. Wibbeling B. Würthwein E.-U. Eur. J. Org. Chem. 2004, 3465

Article in Thieme Connect Google Scholar
2d Sajitz M. Fröhlich R. Salorinne K. Würthwein E.-U. Synthesis 2006, 2183

Article in Thieme Connect Google Scholar
3a Van Otterlo WAL. Pathak R. de Koning CB. Synlett 2003, 1859

Crossref Google Scholar
3b Toda N. Tago K. Marumoto S. Takami K. Ori M. Yamada N. Koyama K. Naruto S. Abe K. Yamazaki R. Hara T. Aoyagi A. Abe Y. Kaneko T. Kogen H. Bioorg. Med. Chem. 2003, 11: 4389

Crossref Google Scholar
For recent reviews on ring-closing metathesis, see:
4a Schrock RR. Hoveyda AH. Angew. Chem. Int. Ed. 2003, 42: 4592

Google Scholar
4b Grubbs RH. Tetrahedron 2004, 60: 7117

Google Scholar
4c Deiters A. Martin F. Chem. Rev. 2004, 104: 2199

Google Scholar
4d Nicolaou KC. Bulger PG. Sarlah D. Angew. Chem. Int. Ed. 2005, 44: 4490

Google Scholar
4e Dragutan I. Dragutan V. Filip P. Arkivoc 2005, (x): 105

Google Scholar
5 For a review on the use of Fisher carbene complexes for heterocyclisation, see: Barluenga J. Martinez S. Arkivoc 2006, (vii): 129

Google Scholar
6 Scholl M. Ding S. Lee CW. Grubbs RH. Org. Lett. 1999, 1: 953

Google Scholar
7 Moonen K. Laureyn I. Stevens CV. Chem. Rev. 2004, 104: 6177

Crossref PubMed Google Scholar
8 Gaffar A. inventors; US 5753633. ; Chem. Abstr. 1998, 129, 8161
9 Danikiewicz W. Makosza M. J. Org. Chem. 1991, 56: 1283

Crossref Google Scholar
10a Dieltiens N. Stevens CV. De Vos D. Allaert B. Drozdzak R. Verpoort F. Tetrahedron Lett. 2004, 45: 8995

Google Scholar
10b Dieltiens N. Stevens CV. Allaert B. Verpoort F. Arkivoc 2005, (i): 92

Google Scholar
10c Moonen K. Dieltiens N. Stevens CV. J. Org. Chem. 2006, 71: 4006

Google Scholar
10d Dieltiens N. Moonen K. Stevens CV. Chem. Eur. J. 2006, in press

Google Scholar
For recent reviews on enyne metathesis, see:
11a Poulson CS. Madson R. Synthesis 2003, 1

Crossref PubMed Google Scholar
11b Diver ST. Giessert AJ. Chem. Rev. 2004, 104: 1317

Crossref PubMed Google Scholar
11c Maifeld SV. Lee D. Chem. Eur. J. 2005, 11: 6118

Crossref PubMed Google Scholar
12a Royer F. Vilain C. Elkaïm L. Grimaud L. Org. Lett. 2003, 5: 2007

Crossref Google Scholar
12b Lee H.-Y. Kim HY. Tae H. Kim BG. Lee J. Org. Lett. 2003, 5: 3439

Crossref Google Scholar
12c Imhof S. Blechert S. Synlett 2003, 609

Crossref Google Scholar
12d Kitamura T. Sato Y. Mori M. Tetrahedron 2004, 60: 9649

Crossref Google Scholar
13 Van Meenen E. Moonen K. Acke D. Stevens CV. Arkivoc 2006, (i): 31

Google Scholar
14 Azizi N. Saidi MR. Tetrahedron 2003, 59: 5329

Crossref Google Scholar
15 Mori M. Sakakibara N. Kinoshita A. J. Org. Chem. 1998, 63: 6082

Google Scholar
16 Lloyd-Jones GC. Margue RG. de Vries JG. Angew. Chem. Int. Ed. 2005, 44: 7442

Google Scholar
17 For a general model for selectivity in cross-metathesis, see: Chatterjee AK. Choi TL. Sanders DP. Grubbs RH. J. Am. Chem. Soc. 2003, 125: 11360

Crossref Google Scholar

18

Synthesis of Derivatives 3 from 4; General Procedure
To a solution of 4 (1 equiv) in anhyd CH₂Cl₂ (15 mL) was added the alkene (5 equiv). This mixture was refluxed under N₂ atmosphere and the second-generation Grubbs’ catalyst 2 (10 mol%) was added. The resulting solution was refluxed for 4 h. The residue was adsorbed onto silica gel and purified by flash chromatography. Synthesis of Derivatives 3 from 5; General Procedure
To a solution of 5 (1 equiv) in anhyd CH₂Cl₂ (15 mL) was added the alkene (5 equiv). This mixture was refluxed under N₂ atmosphere and the second-generation Grubbs’ catalyst 2 (10 mol%) was added. An additional amount of alkene (5 equiv) was added after 2 h and refluxing was continued for an additional 4 h. The residue was adsorbed onto silica gel and purified by flash chromatography. Dimethyl 2-Benzyl-5-[( E )-2-phenylvinyl]-2,3-dihydro-1 H -2-benzazepin-1-ylphosphonate: R _f = 0.27 (EtOAc-MeCN, 8:2). IR: 1031 (PO), 1057 (PO), 1247 (P=O), 1600 (C=C) cm^-1. ¹H NMR (300 MHz, CDCl₃): δ = 2.79 (dd, J = 7.2 Hz, J = 11.6 Hz, 1 H, NCH _AH_BCH), 3.04 (dd, J = 7.2 Hz, J = 11.6 Hz, 1 H, NCH_A H _BCH), 3.50 (d, J = 10.5 Hz, 3 H, OCH₃), 3.62 (d, J = 12.6 Hz, 1 H, NCH _AH_BPh), 3.62 (d, J = 10.7 Hz, 3 H, OCH₃), 4.06 (d, J = 12.6 Hz, 1 H, NCH_A H _BPh), 4.35 (d, J = 25.0 Hz, 1 H, CHP), 6.30 (t, J = 7.2 Hz, 1 H, NCH₂CH), 6.67 (d, J = 16.2 Hz, 1 H, HC=CHPh), 7.00 (d, J = 16.2 Hz, 1 H, HC=CHPh), 7.16-7.47 (m, 13 H, 13 × ArCH), 7.53 (d, J = 7.2 Hz, 1 H, ArCH). ¹³C NMR (75 MHz, CDCl₃): δ = 50.14 (d, J = 5.8 Hz), 53.04 (d, J = 10.4 Hz), 61.48 (d, J = 11.5 Hz), 64.71 (d, J = 171.9 Hz), 126.58, 127.42, 127.96, 128.05, 128.32, 128.43, 128.69, 129.42, 129.50, 129.76, 131.44, 131.61 (d, J = 10.4 Hz), 133.13, 137.45, 138.14 (d, J = 6.9 Hz), 138.63, 143.58. ³¹P NMR (121.5 MHz, CDCl₃): δ = 26.30. MS (ESI): m/z (%) = 446.3 (M + H⁺, 100), 336.2 [M⁺ - P(O)(OMe)₂, 50].
Dimethyl 2-Benzyl-5-(3-trimethylsilanyl-propenyl)-2,3-dihydro-1 H -2-benzazepin-1-ylphosphonate: E/Z, 66:34. R _f = 0.47 (hexane-EtOAc, 2:8). IR: 1033 (PO), 1059 (PO), 1248 (P=O), 1636 (C=C) cm^-1. ¹³C NMR (75 MHz, CDCl₃): δ = 127.28, 127.45, 127.67, 127.80, 127.93, 128.35, 129.21, 129.30, 129.39, 129.45, 129.91, 130.86; where it was possible to assign the chemical shift to a specific isomer, the assignments are given below. ³¹P NMR (121.5 MHz, CDCl₃): δ = 26.33, 26.36. MS (ESI): m/z (%) = 456.2 (M + H⁺, 100), 346.3 [M⁺ - P(O)(OMe)₂, 53]. E-Isomer: ¹H NMR (300 MHz, CDCl₃): δ = 0.03 [s, 9 H, Si(CH₃)₃], 1.59 (d, J = 8.3 Hz, 2 H, CH₂Si), 2.75 (dd, J = 7.0 Hz, J = 11.7 Hz, 1 H, NCH _AH_BCH), 2.86 (dd, J = 7.0 Hz, J = 11.7 Hz, 1 H, NCH_A H _BCH), 3.49 (d, J = 10.5 Hz, 3 H, OCH₃), 3.54 (d, J = 13.2 Hz, 1 H, NCH _AH_BPh), 3.63 (d, J = 10.7 Hz, 3 H, OCH₃), 4.08 (d, J = 13.2 Hz, 1 H, NCH_A H _BPh), 4.29 (d, J = 25.0 Hz, 1 H, CHP), 5.81 (dt, J = 8.3 Hz, J = 15.5 Hz, 1 H, HC=CHCH₂), 5.99 (t, J = 7.0 Hz, 1 H, NCH₂CH), 6.09 (d, J = 15.5 Hz, 1 H, HC=CHCH₂), 7.25-7.46 (m, 18 H, 18 × ArCH). ¹³C NMR (75 MHz, CDCl₃): δ = -1.67, 24.03, 50.12 (d, J = 6.9 Hz), 53.00 (d, J = 5.8 Hz), 53.07 (d, J = 5.8 Hz), 61.19 (d, J = 9.2 Hz), 64.41 (d, J = 168.4 Hz), 123.97, 131.04, 131.30 (d, J = 9.2 Hz), 132.92 (d, J = 2.3 Hz), 133.09 (d, J = 2.3 Hz), 138.83, 139.11 (d, J = 8.1 Hz), 139.79, 144.03. Z-Isomer: ¹H NMR (300 MHz, CDCl₃): δ = 0.02 [s, 9 H, Si(CH₃)₃], 1.64 (d, J = 9.0 Hz, 2 H, CH₂Si), 3.07 (dd, J = 6.4 Hz, J = 13.9 Hz, 1 H, NCH _AH_BCH), 3.17 (dd, J = 6.4 Hz, J = 13.9 Hz, 1 H, NCH_A H _BCH), 3.54 (d, J = 13.4 Hz, 1 H, NCH _AH_BPh), 3.54 (d, J = 10.4 Hz, 3 H, OCH₃), 3.69 (d, J = 10.5 Hz, 3 H, OCH₃), 4.04 (d, J = 13.4 Hz, 1 H, NCH_A H _BPh), 4.36 (d, J = 24.8 Hz, 1 H, CHP), 5.74 (dt, J = 9.0 Hz, J = 12.2 Hz, 1 H, HC=CHCH₂), 6.01 (t, J = 6.4 Hz, 1 H, NCH₂CH), 6.01 (d, J = 12.2 Hz, 1 H, HC=CHCH₂), 7.25-7.46 (m, 18 H, 18 × ArCH). ¹³C NMR (75 MHz, CDCl₃): δ = -1.40, 19.67, 51.27 (d, J = 8.1 Hz), 52.96 (d, J = 6.9 Hz), 53.34 (d, J = 6.9 Hz), 60.30 (d, J = 8.1 Hz), 64.84 (d, J = 166.1 Hz), 130.91 (d, J = 8.1 Hz), 138.87, 139.95 (d, J = 8.1 Hz). Dimethyl 2-Benzyl-5-[(1 E )-5-oxohex-1-enyl]-2,3-dihydro-1 H -2-benzazepin-1-ylphosphonate: R _f = 0.27 (EtOAc-MeCN, 8:2). IR: 1031 (PO), 1057 (PO), 1249 (P=O), 1713 (C=O) cm^-1. ¹H NMR (300 MHz, CDCl₃): δ = 2.15 (s, 3 H, C=OCH₃), 2.42 (dt, J = 6.8 Hz, J = 6.8 Hz, 2 H, CH ₂CH₂C=O), 2.56 (t, J = 6.8 Hz, 2 H, CH₂CH ₂C=O), 2.73 (dd, J = 7.1 Hz, J = 11.9 Hz, 1 H, NCH _AH_BCH), 2.98 (dd, J = 7.1 Hz, J = 11.9 Hz, 1 H, NCH_A H _BCH), 3.47 (d, J = 10.5 Hz, 3 H, OCH₃), 3.59 (d, J = 13.1 Hz, 1 H, NCH _AH_BPh), 3.66 (d, J = 10.5 Hz, 3 H, OCH₃), 4.01 (d, J = 13.1 Hz, 1 H, NCH_A H _BPh), 4.29 (d, J = 25.0 Hz, 1 H, CHP), 5.79 (dt, J = 6.8 Hz, J = 15.5 Hz, 1 H, HC=CHCH₂), 6.08 (t, J = 7.1 Hz, 1 H, NCH₂CH), 6.26 (d, J = 15.5 Hz, 1 H, HC=CHCH₂), 7.23-7.41 (m, 9 H, 9 × ArCH). ¹³C NMR (75 MHz, CDCl₃): δ = 27.16, 30.06, 43.17, 50.07 (d, J = 5.8 Hz), 52.92 (d, J = 6.9 Hz), 53.07 (d, J = 8.1 Hz), 61.41 (d, J = 10.4 Hz), 64.91 (d, J = 171.9 Hz), 126.38, 127.35, 127.82, 128.37, 129.16, 129.45, 131.47, 131.53 (d, J = 9.2 Hz), 131.76, 132.98, 138.49 (d, J = 6.9 Hz), 138.69, 143.06, 208.13. ³¹P NMR (121.5 MHz, CDCl₃): δ = 26.22. MS (ESI): m/z (%) = 439.7 (M + H⁺, 10), 330 [M⁺ - P(O)(OMe)₂, 100].
Dimethyl 2-Benzyl-5-[(1 Z )-5-oxohex-1-enyl]-2,3-dihydro-1 H -2-benzazepin-1-ylphosphonate:
R _f = 0.27 (EtOAc-MeCN, 8:2). IR: 1030 (PO), 1058 (PO), 1252 (P=O), 1714 (C=O) cm^-1. ¹H NMR (300 MHz, CDCl₃): δ = 2.10 (s, 3 H, C=OCH₃), 2.34-2.53 (m, 4 H, CH₂CH₂C=O), 3.01 (dd, J = 6.1 Hz, J = 13.8 Hz, 1 H, NCH _AH_BCH), 3.29 (dd, J = 6.1 Hz, J = 13.8 Hz, 1 H, NCH_A H _BCH), 3.53 (d, J = 10.5 Hz, 3 H, OCH₃), 3.66 (d, J = 13.2 Hz, 1 H, NCH _AH_BPh), 3.71 (d, J = 10.4 Hz, 3 H, OCH₃), 3.94 (d, J = 13.2 Hz, 1 H, NCH_A H _BPh), 4.36 (d, J = 24.8 Hz, 1 H, CHP), 5.61 (dt, J = 7.0 Hz, J = 11.4 Hz, 1 H, HC=CHCH₂), 6.00 (t, J = 6.1 Hz, 1 H, NCH₂CH), 6.13 (d, J = 11.4 Hz, 1 H, HC=CHCH₂), 7.26-7.38 (m, 9 H, 9 × ArCH). ¹³C NMR (75 MHz, CDCl₃): δ = 23.28, 29.90, 43.68, 50.87 (d, J = 6.9 Hz, 52.97 (d, J = 6.9 Hz, 53.29 (d, J = 8.1 Hz), 61.02 (d, J = 9.2 Hz), 65.75 (d, J = 167.3 Hz), 127.33, 127.70, 128.02, 128.37, 128.81, 129.16, 129.39, 131.16, 131.41 (d, J = 9.2 Hz), 131.59, 133.10, 138.74, 139.22 (d, J = 8.1 Hz), 139.53, 208.25. ³¹P NMR (121.5 MHz, CDCl₃): δ = 25.89. MS (ESI): m/z (%) = 439.7 (M + H⁺, 13), 330 [M⁺ - P(O)(OMe)₂, 100].
Dimethyl 2-(4-Bromobenzyl)-4-[(1 E )-4-fenylvinyl]-2,3-dihydro-1 H -2-benzazepin-1-ylphosphonate: R _f = 0.20 (hexane-EtOAc, 4:6). IR: 1031 (PO), 1057 (PO), 1250 (P=O) cm^-1. ¹H NMR (300 MHz, CDCl₃): δ = 3.52 (d, J = 13.6 Hz, 1 H, NCH _AH_BPh), 3.65 (d, J = 10.7 Hz, 3 H, OCH₃), 3.68 (d, J = 11.0 Hz, 3 H, OCH₃), 3.75 (d, J = 13.5 Hz, 1 H, NCH_A H _BPh), 3.95 (d, J = 18.4 Hz, 1 H, NCH _AH_BC), 4.37 (d, J = 18.4 Hz, 1 H, NCH_A H _BC), 4.47 (d, J = 27.5 Hz, 1 H, CHP), 6.46 (d, J = 16.4 Hz, 1 H, HC=CHPh), 6.68 (s, 1 H, C=CHC), 6.89 (d, J = 16.4 Hz, 1 H, HC=CHPh), 7.10-7.42 (m, 13 H, 13 × ArCH). ¹³C NMR (75 MHz, CDCl₃): δ = 53.08 (d, J = 6.9 Hz), 53.65 (d, J = 4.6 Hz), 53.72 (d, J = 6.9 Hz), 57.07, 64.14 (d, J = 155.8 Hz), 121.25, 126.46, 127.33, 127.68, 128.06, 128.09, 128.92, 130.55, 130.92, 131.54, 132.31 (d, J = 4.6 Hz), 132.52, 132.83, 133.74, 136.28 (d, J = 8.1 Hz), 136.57, 137.33, 137.71, 139.27. ³¹P NMR (121.5 MHz, CDCl₃): δ = 25.29. MS (ESI): m/z (%) = 524.03/526.3 (M + H⁺, 60), 414.2/416.2 [M⁺ - P(O)(OMe)₂, 100].
Dimethyl 2-(4-Bromobenzyl)-4-[(1 E )-4-bromobut-1-enyl]-2,3-dihydro-1 H -2-benzazepin-1-ylphosphonate: R _f = 0.29 (hexane-EtOAc, 4:6). IR: 1031 (PO), 1058 (PO), 1252 (P=O) cm^-1. ¹H NMR (300 MHz, CDCl₃): δ = 2.67 (q, J = 7.0 Hz, 2 H, CH ₂CH₂Br), 3.40 (t, J = 7.0 Hz, 2 H, CH₂Br), 3.46 (d, J = 13.5 Hz, 1 H, NCH _AH_BPh), 3.63 (d, J = 10.7 Hz, 3 H, OCH₃), 3.68 (d, J = 10.8 Hz, 3 H, OCH₃), 3.71 (d, J = 13.5 Hz, 1 H, NCH_A H _BPh), 3.79 (d, J = 18.6 Hz, 1 H, NCH _AH_BC), 4.22 (d, J = 18.6 Hz, 1 H, NCH_A H _BC), 4.38 (d, J = 27.8 Hz, 1 H, CHP), 5.54 (dt, J = 7.0 Hz, J = 15.8 Hz, 1 H, HC=CHCH₂), 6.23 (d, J = 15.8 Hz, 1 H, HC=CHCH₂), 6.49 (s, 1 H, C=CHC), 7.10-7.46 (m, 8 H, 8 × ArCH). ¹³C NMR (75 MHz, CDCl₃): δ = 32.39, 36.61, 53.07 (d, J = 6.9 Hz), 53.68 (d, J = 5.8 Hz), 53.68, 57.01, 63.98 (d, J = 154.6 Hz), 121.19, 125.74, 127.21, 128.02, 130.48, 130.89, 131.50, 132.67, 133.62 (d, J = 2.3 Hz), 136.20 (d, J = 6.9 Hz), 136.57, 137.68, 138.67. ³¹P NMR (121.5 MHz, CDCl₃): δ = 25.24. MS (ESI): m/z (%) = 554.0/556.0/558.0 (M + H⁺, 35), 444.0/446.0/448.0 [M⁺ - P(O)(OMe)₂, 100].
Dimethyl 2-(4-Bromobenzyl)-4-[(1 E )-hex-1-enyl]-2,3-dihydro-1 H -2-benzazepin-1-ylphosphonate: R _f = 0.27 (hexane-EtOAc, 4:6). IR: 1031 (PO), 1058 (PO), 1253 (P=O) cm^-1. ¹H NMR (300 MHz, CDCl₃): δ = 0.90 (t, J = 7.0 Hz, 3 H, CH₃), 1.25-1.43 (m, 4 H, CH₂CH₂CH₃), 2.11 (q, J = 6.9 Hz, 2 H, HC=CHCH ₂), 3.46 (d, J = 12.4 Hz, 1 H, NCH _AH_BPh), 3.64 (d, J = 10.7 Hz, 3 H, OCH₃), 3.68 (d, J = 12.1 Hz, 3 H, OCH₃), 3.72 (d, J = 12.4 Hz, 1 H, NCH_A H _BPh), 3.80 (d, J = 18.4 Hz, 1 H, NCH _AH_BC), 4.19 (d, J = 18.4 Hz, 1 H, NCH_A H _BC), 4.39 (d, J = 27.5 Hz, 1 H, CHP), 5.60 (dt, J = 6.9 Hz, J = 16.0 Hz, 1 H, HC=CHCH₂), 6.13 (d, J = 16.0 Hz, 1 H, HC=CHCH₂), 6.44 (s, 1 H, C=CHC), 7.11-7.40 (m, 8 H, 8 × ArCH). ¹³C NMR (75 MHz, CDCl₃): δ = 14.06, 22.35, 31.63, 33.08, 53.00 (d, J = 6.9 Hz), 53.73 (d, J = 8.1 Hz), 53.83 (d, J = 6.9 Hz), 56.80, 63.97 (d, J = 155.8 Hz), 121.18, 126.83, 127.97, 129.85, 130.52, 130.98, 131.45, 133.22, 132.38, 133.64, 136.54 (d, J = 6.9 Hz), 137.76, 139.32. ³¹P NMR (121.5 MHz, CDCl₃): δ = 25.29. MS (ESI): m/z (%) =504.6/506.2 (M + H⁺, 60), 394.2/396.3 [M⁺ - P(O)(OMe)₂, 100].